---
title: "PTGX.US (PTGX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PTGX.US/news.md"
symbol: "PTGX.US"
name: "PTGX.US"
parent: "https://longbridge.com/en/quote/PTGX.US.md"
datetime: "2026-05-22T03:12:03.978Z"
locales:
  - [en](https://longbridge.com/en/quote/PTGX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PTGX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PTGX.US/news.md)
---

# PTGX.US (PTGX.US) — Related News

### [Genvor Appoints Donald Kalkofen as Chief Financial Officer | GNVR Stock News](https://longbridge.com/en/news/287216446.md)
*2026-05-21T04:00:00.000Z*
> Genvor, Inc. has appointed Donald Kalkofen as Chief Financial Officer to lead its financial strategy as the company purs

### [Protagonist Therapeutics President, CEO Sold Shares Worth Over $7.5M](https://longbridge.com/en/news/286168816.md)
*2026-05-12T23:30:00.000Z*
> Dinesh V. Patel, President and CEO of Protagonist Therapeutics, sold shares worth $7.5 million at an average price of $1

### [H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)](https://longbridge.com/en/news/285412538.md)
*2026-05-06T16:37:20.000Z*
> H.C. Wainwright analyst Douglas Tsao has reaffirmed a Buy rating for Protagonist Therapeutics (PTGX) with a price target

### [Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration | PTGX Stock News](https://longbridge.com/en/news/284392137.md)
*2026-04-28T05:05:43.000Z*
> Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration | PTGX Stock News

### [Is It Too Late To Consider Protagonist Therapeutics (PTGX) After A 129% One Year Surge?](https://longbridge.com/en/news/283807786.md)
*2026-04-23T10:08:22.000Z*
> Protagonist Therapeutics (PTGX) has surged 128.7% over the past year, currently priced at approximately $105.55. Analyst